🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

951 results for “Eli” Clear

  1. FB102

    Forteo

    Celiac Disease

    phase 2 mab active

    1 trial

  2. FLORBETAPIR, Placebo to match LY, Flortaucipir, Donanemab

    Eli Lilly Co.

    Alzheimer Disease

    phase 2 small molecule active

    1 trial

  3. FOLINIC ACID, FLUOROURACIL, BEVACIZUMAB, Telisotuzumab adizutecan, FOLINIC ACID, PANITUMUMAB, OXALIPLATIN

    AbbVie Deutschland GmbH & Co. KG

    Metastatic Colorectal Cancer

    phase 2 small molecule active

    1 trial

  4. Fianlimab, LIBTAYO 350 mg concentrate for solution for infusion.

    Disc Medicine

    Metastatic solid tumors, these may include but are not limited to melanoma, non-small-cell lung carcinoma (NSCLC), cervical cancer, microsatellite instable (MSI)-high/deficient mismatch repair (dMMR) cancer, renal cell carcinoma (RCC), CSCC, urothelial cell carcer (UCC), small cell lung cancer (SCLC) and head and neck squamous cell carcinoma (HNSCC).

    phase 2 small molecule active

    1 trial

  5. Fianlimab, LIBTAYO 350 mg concentrate for solution for infusion.

    CERO THERAPEUTICS HOLDINGS, INC.

    Pleural mesothelioma

    phase 2 small molecule active

    1 trial

  6. Flortaucipir, Placebo to match LY3372689

    Eli Lilly Co.

    Alzheimer Disease

    phase 2 small molecule active

    1 trial

  7. Fluciclovine F18

    Telix Innovations

    Prostate Adenocarcinoma

    phase 2 small molecule active

    1 trial

  8. Fluorouracil 50mg/ml Injection., FOLINIC ACID, Eftozanermin alfa, Telisotuzumab adizutecan, Oxaliplatin 5 mg/ml concentrate for solution for infusion

    AbbVie Deutschland GmbH & Co. KG

    Adenocarcinoma of the gastroesophageal junction

    phase 2 small molecule active

    1 trial

  9. Futibatinib, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Taiho Pharma Netherlands B.V.

    Advanced or Metastatic Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  10. GEMCITABINE

    Wuhan Createrna Science and Technology Co., Ltd

    Upper Tract Urothelial Carcinoma. Upper urinary tract transitional cell carcinoma

    phase 2 small molecule active

    1 trial

  11. GSK2330672

    ELITE PHARMACEUTICALS INC /NV/

    Diabetes Mellitus, Type 2

    phase 2 small molecule completed

    1 trial

  12. Galinpepimut-S + Montanide + GM-CSF

    United Therapeutics Europe Ltd

    Malignant Pleural Mesothelioma

    phase 2 mab completed

    1 trial

  13. Gemcitabine Accord 100 mg/ml koncentratas infuziniam tirpalui, Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Padcev 30 mg powder for concentrate for solution for infusion, Zimberelimab, CARBOPLATINE MEDAC 10 mg/mL, solution à diluer pour perfusion, DOMVANALIMAB, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Bavencio 20 mg/mL concentrate for solution for infusion, Trodelvy 200 mg powder for concentrate for solution for infusion

    Gilead Sciences Pty Limited

    Locally Advanced/Metastatic Urothelial Cancer

    phase 2 small molecule active

    1 trial

  14. Gemcitabine/Cisplatin

    BRIGHT MINDS BIOSCIENCES INC.

    Upper Tract Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  15. HAIC + Tislelizumab +lenvatinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hepatocellular Carcinoma (HCC)

    phase 2 other active

    1 trial

  16. HPV DNA Plasmids Therapeutic Vaccine VGX-3100

    INOVIO PHARMACEUTICALS, INC.

    Anal Intraepithelial Neoplasia

    phase 2 mab completed

    1 trial

  17. HYCAMTIN 4 mg powder for concentrate for solution for infusion, TAXOL 6 mg/ml, concentrato per soluzione per infusione., Neulasta 6 mg solution for injection, Caelyx pegylated liposomal 2 mg/ml concentrate for solution for infusion, GEMZAR 1000 mg, poudre pour solution pour perfusion

    SUTRO BIOPHARMA, INC.

    Advanced Epithelial Ovarian Cancer (including Fallopian Tube or Primary Peritoneal cancers)

    phase 2 small molecule active

    1 trial

  18. Hexyon suspension for injection in pre-filled syringe Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and Haemophilus influenzae type b conjugate vaccine (adsorbed)., MenQuadfi solution for injection Meningococcal Group A, C, W and Y conjugate vaccine, RotaTeq oral solution Rotavirus vaccine (live), Bexsero suspension for injection in pre-filled syringe Meningococcal group B Vaccine (rDNA, component, adsorbed), MenPenta SD, Prevenar 13 suspension for in

    Sanofi-aventis Healthcare Pty Ltd

    Meningococcal immunization

    phase 2 small molecule active

    1 trial

  19. IMFINZI 50 mg/mL concentrate for solution for infusion., CAPECITABINE , TREMELIMUMAB

    The George Institute

    Biliary tract cancer

    phase 2 small molecule active

    1 trial

  20. IMFINZI 50 mg/mL concentrate for solution for infusion., TREMELIMUMAB

    Pari Pharma GmbH

    Hepatocellular carcinoma

    phase 2 small molecule active

    1 trial

  21. IMFINZI 50 mg/mL concentrate for solution for infusion., TREMELIMUMAB

    The George Institute

    Intermediate stage hepatocellular carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  22. IMX-110 combined with Tislelizumab

    Immix Biopharma

    Advanced Solid Tumor

    phase 2 small molecule active

    1 trial

  23. INEBILIZUMAB

    Elan Pharma International

    Neuromyelitis optica spectrum disorder (NMOSD; also known as Devic's syndrome and previously known as neuromyelitis optica [NMO])

    phase 2 small molecule active

    1 trial

  24. INO-5401

    INOVIO PHARMACEUTICALS, INC.

    Urothelial Carcinoma

    phase 2 mab completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources